[HTML][HTML] Molecular and cellular mechanisms of action of cannabidiol

N Martinez Naya, J Kelly, G Corna, M Golino, A Abbate… - Molecules, 2023 - mdpi.com
Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …

The polypharmacological effects of cannabidiol

J Castillo-Arellano, A Canseco-Alba, SJ Cutler, F León - Molecules, 2023 - mdpi.com
Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …

Secondary metabolites profiled in cannabis inflorescences, leaves, stem barks, and roots for medicinal purposes

D **, K Dai, Z **e, J Chen - Scientific reports, 2020 - nature.com
Cannabis research has historically focused on the most prevalent cannabinoids. However,
extracts with a broad spectrum of secondary metabolites may have increased efficacy and …

Diversity of molecular targets and signaling pathways for CBD

DL de Almeida, LA Devi - Pharmacology research & …, 2020 - Wiley Online Library
Cannabidiol (CBD) is the second most abundant component of the Cannabis plant and is
known to have effects distinct from Δ9‐tetrahydrocannabinol (THC). Many studies that …

[HTML][HTML] Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders

MS García-Gutiérrez, F Navarrete, A Gasparyan… - Biomolecules, 2020 - mdpi.com
The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain

D De Gregorio, RJ McLaughlin, L Posa… - Pain, 2019 - journals.lww.com
Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

Immune responses regulated by cannabidiol

JM Nichols, BLF Kaplan - Cannabis and cannabinoid research, 2020 - liebertpub.com
Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age

JA Crippa, FS Guimarães, AC Campos… - Frontiers in …, 2018 - frontiersin.org
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …

[HTML][HTML] Cannabidiol as a potential treatment for anxiety disorders

EM Blessing, MM Steenkamp, J Manzanares… - …, 2015 - Elsevier
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum
drug that in recent years has drawn increasing interest as a treatment for a range of …

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

TP Freeman, C Hindocha, G Baio… - The Lancet …, 2020 - thelancet.com
Background A substantial and unmet clinical need exists for pharmacological treatment of
cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which …